摘要
目的在使用基因重组人红细胞生成素（EPO）的情况下,比较静脉用铁剂蔗糖铁（铁泰）、口服铁剂琥珀酸亚铁（速力菲）治疗维持性血液透析患者肾性贫血的有效性和安全性。方法将40例血液透析患者随机分为2组：静脉组患者于透析时使用100 mg蔗糖铁,直至完成总预计补铁量。口服组患者服用琥珀酸亚铁200 mg,3次/d,共12周。2组患者均使用EPO治疗,剂量为每周120-150 IU/kg。观察并比较2组患者贫血治疗的效果、铁代谢指标的变化及不良反应发生情况。结果治疗过程中2组患者平均EPO用量无差异,治疗后2组Hb均较治疗前明显升高,而静脉组Hb上升幅度、铁蛋白和转铁蛋白饱和度均明显高于口服组,不良反应发生率低于口服组。2组患者治疗后血清BUN、SCr、AST、ALP、ALB和CRP等参数均无明显变化。结论蔗糖铁是一种比琥珀酸亚铁更有效的治疗血液透析患者肾性贫血的有效而安全的药物,且不良反应发生率更低。
Objective It is to compare the effectiveness and safety of the treatment with intravenous chalybeatus（Tietai） and that with oral chalybeatus（Sulifei） for renal anemic in patients accepted maintenance hemodialysis on the basis of using EPO.Methods 40 cases of patients accepted hemodialysis were randomly divided into 2 groups： intravenous iron group and oral iron group.The intravenous one was given 100 mg sucrose iron in each dialysis session until total calculated quantity,the oral one was given ferrous succinate 200 mg,three times every day and for 12 weeks.At the same time the both group treated with EPO by 120-150 IU/kg each week.The efficacy on anemic,the changes of indexes of iron metabolism and occurs of side effect were observed and compared between the two groups.Results There was no significant difference in the average dosage used of EPO during treatment between both groups.After treatment,Hb values in both groups increased obviously than that before treatment,but rising degree of Hb and saturation of ferritin and transferrin in the intravenous iron group were higher with less side effect than that in the oral iron group.There was no significant change in the some indexes of BUN,SCr,AST,ALP,ALB and CRP.Conclusion Sucrose iron is a more effective and safer medicament than oral ferrous succinate in the treatment for renal anemic in patients accepted maintenance dialysis with a lower occurring rate of side effect.
出处
《现代中西医结合杂志》
CAS
2011年第10期1175-1176,1178,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
